RediNews
ETFs Holding ACOR »    ACOR Historical Stock Prices »
ACOR News Video: Wed, Jun 21, 2017, 10:31 AM — Wednesday 6/21 Insider Buying Report: ACOR, SBBX


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies for neurological disorders. Co.'s therapies include: Ampyra Extended Release Tablets, 10mg, a treatment to improve walking in patients with multiple sclerosis; Zanaflex Capsules and tablets, a short-acting drugs for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Co.'s registered trademarks include, in the U.S., the marks Acorda Therapeutics, Co.'s stylized Acorda Therapeutics logo, Biotie Therapies, Ampyra, Zanaflex, Zanaflex Capsules, Qutenza and ARCUS. Co. also has trademark registrations for Fampyra and Kampyra. Self directed investors in Acorda Therapeutics Inc will be interested in keeping up with all Acorda Therapeutics Inc news they can find, both ACOR news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACOR. At RediNews, we simplify this task by presenting both ACOR news releases originating from Acorda Therapeutics Inc itself, and ACOR news from a variety of media outlets. Visitors can browse this news online and through our ACOR RSS news feed.

ACOR News

ACOR News — Articles, Videos, & Press Releases

PBE's Underlying Holdings Imply 12% Gain Potential
16 hours, 39 minutes ago — ETF Channel
Top Buys by Top Brass: CEO Cohen's $339K Bet on ACOR
Wednesday, June 21, 2017, 10:31 AM — Dividend Channel
Acorda Presents Phase III Data on PD Candidate CVT-301
Wednesday, June 7, 2017, 3:42 PM — Zacks
Oversold Conditions For Acorda Therapeutics (ACOR)
Thursday, May 25, 2017, 4:24 PM — Dividend Channel
Biogen's Fampyra Conditional Approval Converted to Standard
Thursday, May 25, 2017, 7:16 AM — Zacks
Look Under The Hood: XBI Has 31% Upside
Monday, May 15, 2017, 10:32 AM — ETF Channel
Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss
Friday, April 28, 2017, 8:29 AM — Zacks
Commit To Purchase Acorda Therapeutics At $13, Earn 14.2% Annualized Using Options
Tuesday, April 25, 2017, 11:45 AM — Stock Options Channel
Analysts Predict 10% Gains Ahead For IJS
Friday, April 14, 2017, 8:56 AM — ETF Channel
Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
Thursday, April 6, 2017, 8:10 AM — Zacks
Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge
Monday, April 3, 2017, 7:05 AM — Zacks
Acorda Therapeutics (ACOR) Shares Cross Below 200 DMA
Friday, March 31, 2017, 4:39 PM — Market News Video
Noteworthy Friday Option Activity: AMBA, ACOR, CC
Friday, March 31, 2017, 3:45 PM — Stock Options Channel
Acorda Presents Data for Parkinson's Candidate CVT-301
Thursday, March 30, 2017, 9:30 AM — Zacks
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
Friday, March 17, 2017, 3:58 PM — Zacks
Why Is Acorda (ACOR) Up 10.6% Since the Last Earnings Report?
Friday, March 17, 2017, 5:00 AM — Zacks
Implied PBE Analyst Target Price: $52
Tuesday, March 14, 2017, 9:20 AM — ETF Channel
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
Monday, March 13, 2017, 7:40 AM — Zacks
Noteworthy Thursday Option Activity: EBIX, LOCO, ACOR
Thursday, March 9, 2017, 3:28 PM — Stock Options Channel
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
Wednesday, February 15, 2017, 8:42 AM — Zacks
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
Monday, February 13, 2017, 8:19 AM — Zacks
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
Friday, February 10, 2017, 4:27 PM — Zacks
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
Friday, February 10, 2017, 8:29 AM — Zacks
Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
Friday, February 10, 2017, 8:28 AM — Zacks
Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session
Friday, February 10, 2017, 7:15 AM — Zacks
Notable Wednesday Option Activity: ACOR, AAP, SBAC
Wednesday, February 8, 2017, 3:34 PM — Stock Options Channel
Can Prothena (PRTA) Pull a Surprise This Earnings Season?
Wednesday, February 8, 2017, 3:16 PM — Zacks
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
Wednesday, February 8, 2017, 7:59 AM — Zacks
Can Humana (HUM) Pull a Surprise This Earnings Season?
Monday, February 6, 2017, 1:39 PM — Zacks
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
Friday, February 3, 2017, 9:15 AM — Zacks
GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?
Thursday, February 2, 2017, 9:01 AM — Zacks
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
Thursday, February 2, 2017, 5:46 AM — Zacks
GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
Thursday, February 2, 2017, 5:42 AM — Zacks
First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)
Tuesday, January 24, 2017, 10:59 AM — Stock Options Channel
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
Tuesday, January 24, 2017, 7:14 AM — Zacks
Peek Under The Hood: XBI Has 32% Upside
Wednesday, January 18, 2017, 9:03 AM — ETF Channel
Kura Oncology Starts Dosing Patients in Phase II CMML Study
Wednesday, January 18, 2017, 7:28 AM — Zacks
What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
Tuesday, January 17, 2017, 7:05 AM — Zacks
Noteworthy Friday Option Activity: ITCI, ACOR, SC
Friday, January 6, 2017, 3:29 PM — Stock Options Channel
First Week of February 2017 Options Trading For Acorda Therapeutics (ACOR)
Tuesday, December 20, 2016, 10:48 AM — Stock Options Channel
Noteworthy Wednesday Option Activity: CIEN, ACOR, MTN
Wednesday, December 7, 2016, 3:26 PM — Stock Options Channel
We Did The Math XBI Can Go To $88
Wednesday, December 7, 2016, 9:03 AM — ETF Channel
Acorda Stops Post-Stroke Development Program on Ampyra
Tuesday, November 22, 2016, 7:53 AM — Zacks
Noteworthy Tuesday Option Activity: ACOR, LITE, HAIN
Tuesday, November 15, 2016, 11:26 AM — Stock Options Channel
Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y
Friday, October 28, 2016, 6:25 AM — Zacks
Oversold Conditions For Acorda Therapeutics
Thursday, October 27, 2016, 4:25 PM — Dividend Channel
Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options
Monday, October 17, 2016, 11:37 AM — Stock Options Channel
Add Up The Parts: PBE Could Be Worth $54
Monday, October 3, 2016, 9:41 AM — ETF Channel
Oversold Conditions For Acorda Therapeutics (ACOR)
Thursday, September 29, 2016, 4:27 PM — Dividend Channel
Noteworthy Thursday Option Activity: IONS, ACOR, MON
Thursday, September 8, 2016, 1:16 PM — Stock Options Channel
Peek Under The Hood: PBE Has 30% Upside
Friday, September 2, 2016, 9:32 AM — ETF Channel
Notable Thursday Option Activity: ACOR, PG, SFL
Thursday, August 25, 2016, 3:25 PM — Stock Options Channel
Notable Wednesday Option Activity: ACOR, SQ, AGN
Wednesday, August 3, 2016, 3:28 PM — Stock Options Channel
How The Parts Add Up: PBE Headed For $52
Tuesday, August 2, 2016, 8:52 AM — ETF Channel
Notable Tuesday Option Activity: MXIM, CLF, ACOR
Tuesday, July 26, 2016, 3:31 PM — Stock Options Channel
September 16th Options Now Available For Acorda Therapeutics (ACOR)
Monday, July 18, 2016, 11:23 AM — Stock Options Channel
Add Up The Parts: EWSC Could Be Worth $46
Thursday, June 30, 2016, 7:50 AM — ETF Channel
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Thursday, June 23, 2016, 4:22 PM — Zacks
First Week of August 19th Options Trading For Acorda Therapeutics (ACOR)
Tuesday, June 21, 2016, 10:57 AM — Stock Options Channel
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Tuesday, June 21, 2016, 9:46 AM — Zacks
7 Biotech Stocks that are Buys Right Now
Friday, June 17, 2016, 9:00 AM — Zacks
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Wednesday, June 8, 2016, 8:52 AM — Zacks
Celldex (CLDX) Presents Phase II Melanoma Study Data
Monday, June 6, 2016, 8:45 AM — Zacks
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Friday, May 27, 2016, 12:45 PM — Zacks
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Thursday, May 26, 2016, 9:30 AM — Zacks
Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Monday, May 23, 2016, 5:39 AM — Zacks
Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
Tuesday, May 10, 2016, 7:45 AM — Zacks
VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline
Wednesday, May 4, 2016, 6:09 AM — Zacks
Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus
Friday, April 29, 2016, 8:50 AM — Zacks
Analysts See 10% Gains Ahead For The Holdings of IJT
Tuesday, April 26, 2016, 8:46 AM — ETF Channel
Analysts Forecast 53% Gains Ahead For PBE
Thursday, March 24, 2016, 7:51 AM — ETF Channel
First Week of ACOR May 20th Options Trading
Wednesday, March 23, 2016, 10:39 AM — Stock Options Channel
Acorda Gets Favorable Court Ruling in Ampyra Patent Lawsuit
Tuesday, March 22, 2016, 12:30 PM — Zacks
Oversold Conditions For Acorda Therapeutics (ACOR)
Tuesday, March 15, 2016, 1:16 PM — Dividend Channel
Acorda Therapeutics (ACOR) Shares Cross Above 200 DMA
Wednesday, March 2, 2016, 12:02 PM — Market News Video
IJT's Underlying Holdings Imply 20% Gain Potential
Monday, February 22, 2016, 7:22 AM — ETF Channel
Acorda Q4 Earnings Decline Y/Y, Ampyra & Pipeline in Focus
Friday, February 12, 2016, 9:45 AM — Zacks
Will Teva (TEVA) Continue with its Earnings Streak in Q4?
Wednesday, February 10, 2016, 2:55 PM — Zacks
Why Acorda Therapeutics (ACOR) Might Surprise This Earnings Season
Wednesday, February 10, 2016, 8:10 AM — Zacks
3 Biotech Stocks to Turn the Tide This Earnings Season
Monday, February 8, 2016, 2:59 PM — Zacks
Mylan (MYL) to Report Q4 Earnings: What's in the Cards?
Monday, February 8, 2016, 9:30 AM — Zacks
Should Acorda Therapeutics (ACOR) Be On Your Radar Now?
Tuesday, February 2, 2016, 7:32 AM — Zacks
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q4?
Friday, January 29, 2016, 2:00 PM — Zacks
Allergan's Botox Gains FDA Nod for Lower Limb Spasticity
Tuesday, January 26, 2016, 3:30 PM — Zacks
Will Amgen (AMGN) Continue with the Earnings Streak in Q4?
Tuesday, January 26, 2016, 11:30 AM — Zacks
Will Lilly (LLY) Keep the Earnings Streak Alive in Q4?
Tuesday, January 26, 2016, 10:20 AM — Zacks
Will Biogen (BIIB) Beat 4Q Earnings on MS Franchise Sales?
Monday, January 25, 2016, 3:50 PM — Zacks
Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?
Monday, January 25, 2016, 3:25 PM — Zacks
J&J Plans to Cut 3,000 Medical Devices Jobs, 2015 View Intact
Wednesday, January 20, 2016, 3:35 PM — Zacks
Biotie Therapies Soars on $363M Buyout Deal with Acorda
Wednesday, January 20, 2016, 3:25 PM — Zacks
What Makes Incyte (INCY) a Strong Sell?
Wednesday, January 20, 2016, 7:49 AM — Zacks
Biotie Therapies (BITI) Catches Eye: Stock Moves Up 86.5%
Wednesday, January 20, 2016, 7:15 AM — Zacks
Eleven Biotherapeutics' Eye Drug Fails in Phase III Study
Tuesday, January 19, 2016, 3:30 PM — Zacks
Sarepta Tanks, Eteplirsen Briefing Document Raises Concerns
Monday, January 18, 2016, 1:35 PM — Zacks
Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins
Friday, January 15, 2016, 3:35 PM — Zacks
Is Acorda Therapeutics (ACOR) a Great Growth Stock?
Friday, January 15, 2016, 7:34 AM — Zacks
Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%
Friday, January 15, 2016, 7:15 AM — Zacks
Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus
Wednesday, January 13, 2016, 3:25 PM — Zacks
New Strong Buy Stocks for January 13th
Wednesday, January 13, 2016, 8:30 AM — Zacks
Sangamo Biosciences (SGMO) Worth a Look: Stock Up 9.2%
Wednesday, January 13, 2016, 7:45 AM — Zacks
Acorda's Ampyra Ends 2015 on Strong Note, Pipeline in Focus
Tuesday, January 12, 2016, 8:50 AM — Zacks
Commit To Purchase Acorda Therapeutics At $29, Earn 12.5% Annualized Using Options
Monday, December 7, 2015, 11:33 AM — Stock Options Channel
Bristol-Myers' Opdivo Gets Priority Review from the FDA
Tuesday, November 17, 2015, 12:50 PM — Zacks
Why Acorda Therapeutics (ACOR) Could Be Positioned for a Surge?
Friday, November 6, 2015, 7:52 AM — Zacks
Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
Thursday, October 29, 2015, 7:40 AM — Zacks
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Friday, October 23, 2015, 10:15 AM — Zacks
Acorda Therapeutics Breaks Above 200-Day Moving Average - Bullish for ACOR
Thursday, October 22, 2015, 4:55 PM — Market News Video
Acorda Soars, Settles Ampyra Patent Dispute with Allergan
Tuesday, October 6, 2015, 3:00 PM — Zacks
Acorda Therapeutics (ACOR) Jumps: Stock Moves Up 12%
Tuesday, October 6, 2015, 6:15 AM — Zacks
RSI Alert: Acorda Therapeutics (ACOR) Now Oversold
Monday, September 28, 2015, 12:23 PM — Dividend Channel
Interesting ACOR Put And Call Options For April 2016
Friday, August 28, 2015, 11:32 AM — Stock Options Channel
Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher
Wednesday, August 26, 2015, 7:46 AM — Zacks
Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue
Tuesday, August 25, 2015, 2:40 PM — Zacks
Oversold Conditions For Acorda Therapeutics (ACOR)
Thursday, August 20, 2015, 4:40 PM — Dividend Channel
ACOR Crosses Above Key Moving Average Level
Tuesday, July 14, 2015, 4:29 PM — Market News Video
Acorda Therapeutics Stock Sees Short Interest Decline 10.7%
Tuesday, July 14, 2015, 4:10 PM — Market News Video
Acorda Reports Encouraging Data on MS Drug - Analyst Blog
Thursday, April 23, 2015, 4:16 PM — Zacks
What Makes Novavax (NVAX) a Strong Sell? - Tale of the Tape
Tuesday, March 31, 2015, 7:00 AM — Zacks
2 Stocks to Beat the Dollar's Volatile Run - Analyst Blog
Tuesday, March 24, 2015, 7:45 AM — Zacks
ACOR is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

TSRO News
PBYI News
OHRP News
GMED News
NAVB News
ATRS News
DCTH News
FURX News
CMRX News
ALIM News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACOR News | www.RediNews.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.